Information Provided By:
Fly News Breaks for September 21, 2017
ICPT
Sep 21, 2017 | 15:41 EDT
Baird analyst Brian Skorney would continue to be a buyer of Intercept on today's selloff, saying it is an overreaction to a drug safety communication that is more detailed than last week's "Dear HCP" letter but is nothing that he views as a concern given the characteristics of these patients. Skorney views the selloff as "extreme" and reiterates his Outperform rating and $332 price target on Intercept shares, which are down over 22% heading into the close.
News For ICPT From the Last 2 Days
There are no results for your query ICPT